Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.55 |
| ▸ | RAB9A | P51151 | 10/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 11/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | GRK6 | P43250 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14619107 | 0.86 | MAPT (0.56) | NPC1RAB9ASMN1; SMN2USP2MAPK10 | |
| SCHEMBL29802262 | 0.86 | MAPT (0.56) | NPC1RAB9ASMN1; SMN2USP2MAPK10 | |
| SCHEMBL993416 | 0.86 | GRK6 (0.64) | NPC1RAB9ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL29236840 | 0.84 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2USP2MAPK10 | |
| SCHEMBL21814974 | 0.83 | MEN1 (0.56) | NPC1RAB9ASMN1; SMN2USP2MAPK10 | |
| SCHEMBL11792767 | 0.82 | MAPT (0.51) | NPC1RAB9ASMN1; SMN2USP2MAPK10 | |
| SCHEMBL3972207 | 0.81 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2USP2MAPK10 | |
| SCHEMBL5540534 | 0.80 | KDM4E (0.77) | NPC1RAB9ASMN1; SMN2USP2MAPK10 | |
| SCHEMBL10222344 | 0.80 | GAA (0.53) | NPC1RAB9ASMN1; SMN2USP2MAPK10 | |
| SCHEMBL20049339 | 0.79 | MAPT (0.50) | NPC1RAB9ASMN1; SMN2USP2MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | NPC1 2208/4885RAB9A 1340/4885SMN1; SMN2 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.